April 8, 2020   Company Press Releases

Agreement Will Significantly Expand Patient Access to Therapeutic iNO Beyond the Existing $800M+ Global Hospital Market Waltham, MA – April 8, 2020 – Third Pole Therapeutics, a privately held company developing and delivering critical life-sustaining cardio-pulmonary therapies, announced it has entered into a global license, development and commercialization agreement with Chiesi Farmaceutici, an international research-focused pharmaceutical group (Chiesi Group). >> …

  April 8, 2020   News/Publications

Critical care and emergency medicine faculty at the LSU Health Shreveport Department of Medicine join the Department of Anesthesia at Massachusetts General Hospital (MGH) and the Division of Cardiology in the Department of Medicine at University of Alabama-Birmingham (UAB) as being among the first centers in the United States to enroll patients in an international study testing using inhaled nitric oxide to improve outcomes for COVID-19 patients with severely damaged lungs; using gas to effectively “kill” coronavirus in the lungs and improve delivery of oxygen to injured tissues.

  August 21, 2019   Company Press Releases

Newest Patents Cover Nitric Oxide Generation and Wearable Delivery Systems Arlington, MA – August 21, 2019 – Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced today that the U.S. Patent and Trademark Office has recently issued U.S. patents covering Third Pole’s innovative general and portable inhaled Nitric Oxide (iNO) delivery systems. >> Read …